855 Spam-Free Article(s) Found
Jun 19, 2019 -
Midway through trading Wednesday, the Dow traded up 0.04% to 26476.32 while the NASDAQ fell 0.06% to 7948.95. The S&P also fell, dropping 0.03% to 2,917.02.
Leading and Lagging Sectors
Jun 19, 2019 - Gainers: Melinta Therapeutics (NASDAQ:MLNT) +144%. Arcturus Therapeutics (NASDAQ:ARCT) +35%. MYOS RENS Technology (NASDAQ:MYOS) +23%. Enlivex Therapeutics (NASDAQ:ENLV) +11%. Concord Medical Services
Jun 19, 2019 -
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks Hitting 52-week highs on June 18)
Jun 19, 2019 - Provention Bio was able to show that those given PRV-031 were able to delay the onset of Type 1 Diabetes in a study known as At Risk.PRV-031 is also being explored in a phase 3 study to treat patients
Jun 18, 2019 -
Jun 18, 2019 - Unity Biotechnology (NASDAQ:UBX) has announced results from its first-in-human Phase 1 study of UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee. The study demonstr
Jun 17, 2019 -
Invitae (NYSE: NVTA) will acquire Singular Bio for $55 million in a mostly stock deal.
Jun 15, 2019 - Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
Jun 14, 2019 - After decades of fairy tale wishes, we're now close to the reality of having a medicine that can simultaneously delay Type 1 diabetes on-set and prevent its occurrence.Provention Bio brought the sweet
Jun 13, 2019 - The New York Department of Health has issued a laboratory permit to Bio-Techne (NASDAQ:TECH) to provide its ExoDx Prostate Intelliscore test there.The company has performed over 25K tests since its 20